Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The hypothesis is that the SGLT-2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure, and if the hypothesis is proven, that this mechanism contributes to the beneficial effects found in EMPA-REG Outcome trial potentially via exerting beneficial effects on the vascular structure and function of the micro- and macrocirculation.
Epistemonikos ID: ff99088c28cd87bf482a1f6a21818c57727c1893
First added on: May 20, 2024